Immunotherapy is a hot-topic field of research that has generated significant scientific interest and fuelled industrial innovation.
It has been demonstrated that small, drug-like molecules can be highly effective modulators of immune response pathways and that their molecular properties can be fine-tuned to enable excellent cell permeability and bioavailability. This makes them ideal for use in the treatment of chronic conditions such as autoimmune and inflammation-related diseases. Excitingly, this approach also offers the possibility to treat cancer by harnessing the body’s own immune system to fight tumours.
This meeting will offer a broad introduction to those new to the topic and showcase recent innovations by academic and industrial scientists in this exciting and rapidly expanding field.
The event is targeted at research students, researchers, academic and industrial scientists engaged in all aspects of research into small molecule immunotherapy, and those interested in broadening their knowledge in this growing field.
The programme will be announced in due course. Confirmed speakers:
“Optimisation of Mer/Axl kinase inhibitors for immuno-oncology”, Dr William McCoull - Associate Director AZ
“The discovery of BD2 selective BET inhibitors”, Emmanuel Demont - GSK
Booking terms and conditions
For further information and prices, please email email@example.com
- Tilly Bingham, SCI/ Concept Life Sciences
- Nicola Chessum, SCI
- Jayshree Mistry, SCI/ Modgraph Consultants
Tel: +44 (0)20 7598 1561